Companies
Cellectis
FDA RMAT designation June 2026 for allogeneic TALEN-edited UCART22 in r/r B-ALL; Phase 1 100% response rate; pivotal trial initiated — only allogeneic CAR-T in a pivotal trial globally.
- Country
- France
- Ticker
- CLLS
Coverage
| CN | EU | US | |
|---|---|---|---|
| regenerative-personalized | ✓ | ✓ | ✓ |
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Revenue | $14.5 million in consolidated revenues and other income for the six-month period ended June 30, 2026 | ml.globenewswire.com |
| Production site | Paris, France (55,000 sq ft facility); Raleigh, NC (82,000 sq ft facility); New York, NY (25,000 sq ft facility) | cellectis.com |
| Capacity | 1 batch produces 100s of doses, scalable to 1000s of doses medium confidence | cellectis.com |
| Regulatory approval | FDA RMAT designation granted to lasme-cel (UCART22) in June 2026 | allsci.com · finance.yahoo.com · cellectis.com |
| Headquarters | Paris, France | finance.yahoo.com · cellectis.com |
| Funding | $169 million in consolidated cash, cash equivalents and fixed-term deposits as of June 30, 2026 | ml.globenewswire.com · cellectis.com |
Independent sources: allsci.com · finance.yahoo.com · ml.globenewswire.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| CAR-T cell therapy | therapeutics-platforms | Low | → |
| Personalized & regenerative medicine | regenerative-personalized | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.